Baird analyst Wesley Golladay lowered the firm’s price target on Healthpeak Properties (DOC) to $24 from $25 and keeps an Outperform rating on the shares. The firm noted its Q4 results suggest the company is deploying capital om multiple fronts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Potential Regulatory Changes Threaten Healthpeak Properties’ Investment in Healthcare Real Estate
- Healthpeak Properties: Strong Q4 Performance and Strategic Initiatives Justify Buy Rating
- Healthpeak Properties Reports Strong 2024 Results
- Healthpeak Properties Highlights Earnings Growth Amid Challenges
- Healthpeak Properties Reports Strong 2024 Financial Results